Allergan CEO wins $13.6M in total comp

The CEO of the cosmetic therapy developer Allergan won $13.6 million in total compensation for last year, a 20 percent hike over 2007. David E.I. Pyott's pay was detailed in the company's latest SEC filing.

Most of the increase, though, came from stock awards that are now worth a whole lot less than when they were granted in early 2008. His options and restricted stock were worth $10.9 million when the shares were issued. But Allergan's stock has sunk as the demand for its cosmetic therapies--including Botox--declined. Its shares are now trading around $40.

Pyott's salary came in at $1.35 million, up a modest 4.4 percent.

- read the AP report

Also: Wall Street is abuzz today with talk that Allergan may be on the block. Options traders have snapped up 13,000 April contracts--way beyond the normal volume. Apparently, they were set in motion by a web report that GlaxoSmithKline might be interested in the company. Report

Related Articles:
Bristol, Allergan chiefs nab big raises
Anticipating sales declines, Allergan cuts 460
FDA approves Allergan's eyelash-growth drug
Cosmetic pharma remains steady in downturn